Closing Roundtable Session: Future Directions & Implementations for Our Anti-HER2 Drug Development Efforts’

Time: 3:30 pm
day: Day Two

Details:

• Tables thoughts and rationale on potential best combinations for own HER2 agents
• Tables thoughts on biosimilars
• Peers thoughts on understanding the effects and pathology on downstream signaling when resistance arises
• Peers thoughts on the movement towards considering the entire patient journey in treatment & regulatory input
• Are HER2 antagonists interesting to the table?
• Thoughts on dealing with the lack of homogeneity – future directions and how to advance this space
• Peers views on designing for approval in monotherapy vs combination therapy
• Opinions on how to best take novel targets into the clinic
• Tables thoughts on disease selection & challenges that come with it
• Opinions on where is this field going?